Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder
Source Nature 医学研究19h ago
Summary
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Health
- Region
- Global
- Language
- English
- Item ID
- health-56a8901c
Comments 0 comments
No comments yet. Be the first.